Research programme: recombinant bioheparin - Biotie Therapies

Drug Profile

Research programme: recombinant bioheparin - Biotie Therapies

Alternative Names: BioHeparin

Latest Information Update: 20 Jul 2010

Price : $50

At a glance

  • Originator Biotie Therapies Corp.
  • Class Heparins; Recombinant proteins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 20 Jul 2010 Discontinued - Preclinical for Thrombosis in Finland (unspecified route)
  • 01 Nov 2006 This compound is still in active development
  • 19 Oct 2005 Biotie and sanofi-aventis have agreed not to renew the option agreement for this programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top